Two medicines, side by side
Mirabegron vs trospium
Mirabegron and trospium are both labeled for overactive bladder. Drugs@FDA records approvals of mirabegron since 2012 and of trospium since 2004. Pharmacies paid $9.39 per mirabegron ER 50 mg tablet and $0.211 per trospium chloride 20 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, mirabegron is a beta3-adrenergic agonist and trospium a cholinergic muscarinic antagonist.
Check it at the source: the mirabegron FDA label on DailyMed (effective December 24, 2025); the trospium FDA label on DailyMed (effective December 30, 2025).
Highlights of the mirabegron record
Mirabegron (Myrbetriq) · label of December 24, 2025
Used for
From the label: indicationsMirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. […]
On the market
- Earliest approval on file
- June 28, 2012
- Generic labelers
- 8 labelers
- Pharmacy cost
- $9.39 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Highlights of the trospium record
Trospium (Sanctura) · label of December 30, 2025
Used for
From the label: indicationsTrospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
On the market
- Earliest approval on file
- May 28, 2004
- Generic labelers
- 19 labelers
- Pharmacy cost
- $0.211 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Source: FDA drug labels via openFDA (Mirabegron label of December 24, 2025, Trospium label of December 30, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do mirabegron and trospium differ on the record?
In FDA's classes, mirabegron is a beta3-adrenergic agonist and trospium a cholinergic muscarinic antagonist.
How each works, in its label's words: Mirabegron, “Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR.”; Trospium, “Trospium chloride is a muscarinic antagonist.”
Half-life, in each label's words: Mirabegron, “Elimination Mirabegron Extended-Release Tablets Monotherapy for Adult OAB: The terminal elimination half-life (t 1/2 ) …”; Trospium, “Excretion: The plasma half-life for trospium chloride following oral administration is approximately 20 hours.”
Generics: mirabegron since 2019; trospium since 2010 (Drugs@FDA).
| Mirabegron | Trospium | |
|---|---|---|
| Labeled for | Overactive bladder | Overactive bladder |
| Pharmacologic class | beta3-Adrenergic Agonist | Cholinergic Muscarinic Antagonist |
| How it works (label) | Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in vitro laboratory experiments using the cloned human beta-3 AR. | Trospium chloride is a muscarinic antagonist. Trospium chloride antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs including the bladder. |
| Half-life (label) | Elimination Mirabegron Extended-Release Tablets Monotherapy for Adult OAB: The terminal elimination half-life (t 1/2 ) of mirabegron is approximately 50 hours in patients. | Excretion: The plasma half-life for trospium chloride following oral administration is approximately 20 hours. |
| Earliest approval on file (Drugs@FDA) | June 28, 2012 | May 28, 2004 |
| First generic approved | December 27, 2019 | August 13, 2010 |
| Generic labelers (NDC) | 8 labelers | 19 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $9.39 per tablet (Mirabegron ER 50 mg tablet) | $0.211 per tablet (Trospium chloride 20 mg tablet) |
| 12-month price change | -2% | -25% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 1 | 1 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 38,466 | 2,273 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Trospium label, drug interactionsThe concomitant use of trospium chloride with other antimuscarinic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.
Source: FDA drug labels via openFDA
What next?
- Alternatives to mirabegron
- every medicine labeled for the same conditions